{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:11:32Z","timestamp":1789269092987,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Takeda Pharmaceutical Company Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12185-020-03039-w","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T22:03:09Z","timestamp":1609711389000},"page":"404-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety profile of brentuximab vedotin in Japanese patients with relapsed\/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"issue":"4","key":"3039_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/mabs.20230","volume":"4","author":"NW van de Donk","year":"2012","unstructured":"van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs. 2012;4(4):458\u201365.","journal-title":"MAbs"},{"key":"3039_CR2","unstructured":"Seattle Genetics Inc. ADCETRIS\u00ae (brentuximab vedotin) for injection, for intravenous use, US Prescribing Information. 2019. https:\/\/seagendocs.com\/Adcetris_Full_Ltr_Master.pdf."},{"issue":"18","key":"3039_CR3","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30(18):2183\u20139.","journal-title":"J Clin Oncol"},{"issue":"18","key":"3039_CR4","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190\u20136.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3039_CR5","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562\u20136.","journal-title":"Blood"},{"issue":"25","key":"3039_CR6","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709\u201317.","journal-title":"Blood"},{"key":"3039_CR7","first-page":"2359437","volume":"2016","author":"Y Sabet","year":"2016","unstructured":"Sabet Y, Ramirez S, Rosell Cespedes E, Rensoli Velasquez M, Porres-Munoz M, Gaur S, et al. Severe acute pulmonary toxicity associated with brentuximab in a patient with refractory Hodgkin\u2019s lymphoma. Case Rep Pulmonol. 2016;2016:2359437.","journal-title":"Case Rep Pulmonol"},{"issue":"7","key":"3039_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/cas.12435","volume":"105","author":"M Ogura","year":"2014","unstructured":"Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, et al. Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840\u20136.","journal-title":"Cancer Sci"},{"key":"3039_CR9","unstructured":"Takeda Pharmaceutical Co. Ltd. ADCETRIS\u00ae, Japan package insert [in Japanese]. 2018. https:\/\/www.info.pmda.go.jp\/go\/pack\/4291425D1021_1_11\/."},{"issue":"5","key":"3039_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s12185-021-03091-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03039-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-03039-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03039-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:44:58Z","timestamp":1744181098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-03039-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["3039"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03039-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12185-021-03091-0","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-021-03091-0","URL":"https:\/\/doi.org\/10.1007\/s12185-021-03091-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KI reports non-financial support from Takeda during the conduct of the study; grants, personal fees or both from Takeda, Chugai, Celgene, Novartis, Abbvie, Janssen, Kyowa Kirin, Eisai, Merck, Sharp & Dohme, Astra Zeneca, FUJIFILM Toyama Chemical, Ono  Pharmaceutical, Nihon Mediphysics, Dainihon Sumitomo, Bayer, HUYA Japan, Bristol Myers Squibb, Mundi Pharma, Otsuka, Daiichi Sankyo, Astellas and Asahi Kasei Pharma, outside the submitted work. MO reports personal fees from Celgene, Denovo Biopharma, Mundi Pharma, Meiji Seika Pharma, Celtrion, Verastem, Eisai and Teva Takeda, outside the submitted work. KT reports grants and personal fees from Takeda during the conduct of the study; grants, personal fees or both from Merck, Celgene, Daiichi Sankyo, HUYA Bioscience International, Mundipharma, Ono Pharmaceutical, Zenyaku Kogyo, Bristol Myers Squibb, Chugai, Eisai, Janssen, Kyowa Kirin, Meiji Seika, Solasia Pharma, Verastem, Yakult and Abbvie, outside the submitted work. KH report personal fees from Takeda, outside the submitted work. SS, MN and MH report employment with Takeda Pharmaceutical Co. Ltd. during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}